Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | FNTA | P49354 | 2/20 | 0.55 |
| ▸ | FNTB | P49356 | 2/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244201 | 0.85 | PPARG (0.47) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL6669751 | 0.82 | KDM4E (0.68) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL4975424 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL29477149 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL8178846 | 0.80 | ALDH1A1 (0.47) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL8174900 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL5211637 | 0.79 | ALDH1A1 (0.68) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL7463580 | 0.78 | KDM4E (0.71) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL11216214 | 0.77 | KDM4E (0.54) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL8166735 | 0.77 | KDM4E (0.44) | KDM4EALDH1A1GAAMAPTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | KDM4E 2605/4885ALDH1A1 1932/4885GAA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.